Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06531863 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 14, 2025 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Not applicable to Early Phase 1v5 Show 5 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Primary completion date: Jan 1, 2025 to May 1, 2025
    • Start date changed from estimate of Sep 1, 2024 to Sep 30, 2024
    • Eligibility criteria shortened, about 2 words
  2. Re-verified, no change to tracked fieldsv4
  3. Study description revisedv3
  4. Secondary endpoints revised (7)v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)
Trial Details
NCT Number NCT06531863
Lead Sponsor Auburn University
Conditions
(from sponsor)		 Mood Disturbance
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov